Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial

Published:2018-11 Issue:11 Volume:18 Page:1241-1250
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Delany-Moretlwe Sinead,Lombard Carl,Baron Deborah,Bekker Linda-Gail,Nkala Busi,Ahmed Khatija,Sebe Modulakgotla,Brumskine William,Nchabeleng Maposhane,Palanee-Philips Thesla,Ntshangase Julius,Sibiya Sidney,Smith Emilee,Panchia Ravindre,Myer Landon,Schwartz Jill L,Marzinke Mark,Morris Lynn,Brown Elizabeth R,Doncel Gustavo F,Gray Glenda,Rees Helen

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference36 articles.

1. Prevention gap report,2016

2. South African national HIV prevalence, incidence and behaviour survey, 2012;Shisana,2014

3. Topical microbicides for prevention of sexually transmitted infections;Obiero;Cochrane Database Syst Rev,2012

4. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine;Parikh;J Virol,2009

5. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques;Dobard;Retrovirology,2015

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Control groups for HIV prevention efficacy trials: what does the future hold?;Current Opinion in HIV and AIDS;2023-09-11

2. Sustained Delivery of the Antiviral Protein Griffithsin and Its Adhesion to a Biological Surface by a Silk Fibroin Scaffold;Materials;2023-08-09

3. Single-nucleotide polymorphisms in ABC drug transporters alter expression and circulating tenofovir in healthy South African women exposed to pre-exposure prophylaxis;Pharmacogenomics;2023-07

4. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir;Frontiers in Cellular and Infection Microbiology;2023-04-19

5. Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention;Frontiers in Immunology;2022-12-06